Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Tuberculosis, Multidrug-Resistant | 40 | 2019 | 912 | 2.180 |
Why?
|
Antitubercular Agents | 42 | 2019 | 1320 | 1.830 |
Why?
|
Directly Observed Therapy | 10 | 2012 | 137 | 0.960 |
Why?
|
Peru | 42 | 2019 | 881 | 0.950 |
Why?
|
Tuberculosis, Pulmonary | 14 | 2019 | 810 | 0.880 |
Why?
|
Extensively Drug-Resistant Tuberculosis | 6 | 2017 | 92 | 0.740 |
Why?
|
Mycobacterium tuberculosis | 24 | 2019 | 1832 | 0.710 |
Why?
|
Drug Resistance, Multiple, Bacterial | 11 | 2015 | 567 | 0.610 |
Why?
|
Tuberculosis | 15 | 2016 | 1912 | 0.500 |
Why?
|
Social Support | 6 | 2011 | 2118 | 0.460 |
Why?
|
Sputum | 13 | 2019 | 476 | 0.410 |
Why?
|
Contact Tracing | 5 | 2019 | 273 | 0.390 |
Why?
|
Antiretroviral Therapy, Highly Active | 4 | 2011 | 1872 | 0.360 |
Why?
|
Community Health Services | 7 | 2012 | 650 | 0.310 |
Why?
|
HIV Infections | 14 | 2016 | 16715 | 0.280 |
Why?
|
Developing Countries | 10 | 2016 | 2815 | 0.250 |
Why?
|
Microbial Sensitivity Tests | 13 | 2019 | 1877 | 0.250 |
Why?
|
Health Services | 2 | 2011 | 758 | 0.240 |
Why?
|
Preventive Health Services | 1 | 2006 | 575 | 0.200 |
Why?
|
Poverty | 7 | 2016 | 2660 | 0.190 |
Why?
|
Residence Characteristics | 1 | 2010 | 2050 | 0.190 |
Why?
|
Drug Resistance, Multiple | 4 | 2008 | 252 | 0.180 |
Why?
|
Information Systems | 1 | 2002 | 410 | 0.170 |
Why?
|
Anti-HIV Agents | 3 | 2011 | 4255 | 0.170 |
Why?
|
Medical Records Systems, Computerized | 2 | 2004 | 1205 | 0.170 |
Why?
|
Family Characteristics | 4 | 2013 | 1000 | 0.150 |
Why?
|
Pyrazinamide | 2 | 2015 | 54 | 0.140 |
Why?
|
Mental Health | 1 | 2011 | 3014 | 0.140 |
Why?
|
Rifampin | 4 | 2019 | 315 | 0.130 |
Why?
|
Quality of Health Care | 2 | 2014 | 4369 | 0.120 |
Why?
|
Delivery of Health Care | 2 | 2016 | 5321 | 0.120 |
Why?
|
Mycobacterium | 1 | 2015 | 249 | 0.120 |
Why?
|
Entamoebiasis | 1 | 2013 | 14 | 0.120 |
Why?
|
Protozoan Infections | 1 | 2013 | 39 | 0.120 |
Why?
|
Giardiasis | 1 | 2013 | 28 | 0.120 |
Why?
|
Amebiasis | 1 | 2013 | 34 | 0.120 |
Why?
|
Blastocystis Infections | 1 | 2013 | 16 | 0.120 |
Why?
|
Developed Countries | 1 | 2016 | 437 | 0.120 |
Why?
|
Clinical Laboratory Information Systems | 1 | 2014 | 108 | 0.110 |
Why?
|
Urban Population | 3 | 2011 | 2022 | 0.110 |
Why?
|
Qualitative Research | 2 | 2011 | 2682 | 0.100 |
Why?
|
Drug Resistance, Bacterial | 2 | 2010 | 1035 | 0.100 |
Why?
|
Russia | 4 | 2017 | 408 | 0.100 |
Why?
|
Adult | 38 | 2019 | 214056 | 0.090 |
Why?
|
Anthropology, Cultural | 1 | 2010 | 99 | 0.090 |
Why?
|
National Health Programs | 2 | 2011 | 445 | 0.090 |
Why?
|
Antibiotics, Antitubercular | 3 | 2005 | 104 | 0.090 |
Why?
|
Humans | 66 | 2019 | 744376 | 0.080 |
Why?
|
Financial Management | 1 | 2010 | 160 | 0.080 |
Why?
|
Young Adult | 18 | 2019 | 56434 | 0.080 |
Why?
|
Family Health | 1 | 2013 | 1281 | 0.080 |
Why?
|
Models, Organizational | 1 | 2011 | 574 | 0.080 |
Why?
|
Treatment Outcome | 20 | 2015 | 63115 | 0.080 |
Why?
|
Treatment Failure | 4 | 2016 | 2618 | 0.070 |
Why?
|
Isoniazid | 3 | 2019 | 274 | 0.070 |
Why?
|
Verbal Behavior | 1 | 2008 | 339 | 0.070 |
Why?
|
Male | 38 | 2019 | 350118 | 0.070 |
Why?
|
Adolescent | 19 | 2019 | 85784 | 0.070 |
Why?
|
Population Surveillance | 4 | 2011 | 2616 | 0.070 |
Why?
|
Female | 40 | 2019 | 380200 | 0.070 |
Why?
|
Stereotyping | 1 | 2008 | 241 | 0.070 |
Why?
|
HIV Seropositivity | 1 | 2012 | 971 | 0.070 |
Why?
|
Health Services Needs and Demand | 2 | 2011 | 1410 | 0.070 |
Why?
|
Trust | 1 | 2010 | 505 | 0.070 |
Why?
|
Focus Groups | 1 | 2010 | 1321 | 0.070 |
Why?
|
Food Supply | 1 | 2011 | 524 | 0.070 |
Why?
|
Cohort Studies | 12 | 2016 | 40558 | 0.070 |
Why?
|
Medical Errors | 1 | 2014 | 1297 | 0.070 |
Why?
|
Drug Therapy, Combination | 7 | 2015 | 6489 | 0.070 |
Why?
|
Incidence | 8 | 2019 | 20950 | 0.060 |
Why?
|
Treatment Refusal | 1 | 2008 | 421 | 0.060 |
Why?
|
Models, Theoretical | 1 | 2017 | 3589 | 0.060 |
Why?
|
Pregnancy Complications, Infectious | 2 | 2009 | 2026 | 0.060 |
Why?
|
Social Stigma | 1 | 2011 | 701 | 0.060 |
Why?
|
Middle Aged | 20 | 2019 | 213388 | 0.060 |
Why?
|
Government Programs | 1 | 2006 | 275 | 0.060 |
Why?
|
Retrospective Studies | 19 | 2015 | 77459 | 0.060 |
Why?
|
Medication Systems, Hospital | 1 | 2004 | 158 | 0.060 |
Why?
|
Community-Institutional Relations | 1 | 2004 | 204 | 0.060 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2011 | 941 | 0.050 |
Why?
|
DNA-Directed RNA Polymerases | 1 | 2005 | 371 | 0.050 |
Why?
|
Mass Screening | 2 | 2011 | 5255 | 0.050 |
Why?
|
Social Environment | 1 | 2007 | 1023 | 0.050 |
Why?
|
Proportional Hazards Models | 5 | 2016 | 12356 | 0.050 |
Why?
|
Prospective Studies | 9 | 2019 | 53291 | 0.050 |
Why?
|
Child, Preschool | 8 | 2019 | 41005 | 0.050 |
Why?
|
Information Management | 1 | 2002 | 101 | 0.050 |
Why?
|
Prevalence | 6 | 2016 | 15221 | 0.050 |
Why?
|
Cost of Illness | 1 | 2010 | 1860 | 0.050 |
Why?
|
Latvia | 2 | 2012 | 14 | 0.050 |
Why?
|
Primary Health Care | 1 | 2016 | 4557 | 0.050 |
Why?
|
Estonia | 2 | 2012 | 53 | 0.050 |
Why?
|
Philippines | 2 | 2012 | 86 | 0.040 |
Why?
|
Medication Adherence | 1 | 2011 | 2063 | 0.040 |
Why?
|
Communication | 1 | 2014 | 3750 | 0.040 |
Why?
|
Adaptation, Psychological | 1 | 2010 | 2575 | 0.040 |
Why?
|
Lesotho | 2 | 2011 | 70 | 0.040 |
Why?
|
Socioeconomic Factors | 5 | 2012 | 7785 | 0.040 |
Why?
|
Time Factors | 7 | 2013 | 40077 | 0.040 |
Why?
|
Endemic Diseases | 1 | 2000 | 182 | 0.040 |
Why?
|
Language | 1 | 2008 | 1471 | 0.040 |
Why?
|
Tuberculin Test | 1 | 2019 | 214 | 0.040 |
Why?
|
Emotions | 1 | 2010 | 2658 | 0.040 |
Why?
|
Patient Compliance | 2 | 2006 | 2685 | 0.040 |
Why?
|
Methicillin Resistance | 1 | 1999 | 198 | 0.040 |
Why?
|
Infant | 5 | 2019 | 35134 | 0.040 |
Why?
|
Primary Prevention | 2 | 2010 | 1167 | 0.040 |
Why?
|
Child | 10 | 2019 | 77708 | 0.040 |
Why?
|
Substance-Related Disorders | 2 | 2012 | 4257 | 0.040 |
Why?
|
Environmental Exposure | 1 | 2013 | 4232 | 0.040 |
Why?
|
Health Resources | 1 | 2004 | 911 | 0.040 |
Why?
|
Clinical Protocols | 3 | 2015 | 1462 | 0.040 |
Why?
|
Drug Administration Schedule | 5 | 2006 | 4933 | 0.040 |
Why?
|
Medication Errors | 1 | 2004 | 798 | 0.040 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2003 | 685 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 2 | 2019 | 6539 | 0.040 |
Why?
|
Risk Factors | 10 | 2017 | 72295 | 0.040 |
Why?
|
Anti-Retroviral Agents | 1 | 2006 | 1714 | 0.040 |
Why?
|
User-Computer Interface | 1 | 2004 | 1431 | 0.040 |
Why?
|
Case-Control Studies | 5 | 2014 | 21747 | 0.030 |
Why?
|
Drug Monitoring | 1 | 2002 | 956 | 0.030 |
Why?
|
Asia | 1 | 2017 | 609 | 0.030 |
Why?
|
Aged | 10 | 2019 | 163284 | 0.030 |
Why?
|
Research Design | 2 | 2014 | 5986 | 0.030 |
Why?
|
Entamoeba | 1 | 2013 | 6 | 0.030 |
Why?
|
Endolimax | 1 | 2013 | 7 | 0.030 |
Why?
|
Blastocystis hominis | 1 | 2013 | 7 | 0.030 |
Why?
|
Follow-Up Studies | 5 | 2019 | 39052 | 0.030 |
Why?
|
Giardia lamblia | 1 | 2013 | 23 | 0.030 |
Why?
|
Health Services Accessibility | 1 | 2011 | 5135 | 0.030 |
Why?
|
Sex Distribution | 2 | 2011 | 2297 | 0.030 |
Why?
|
South Africa | 1 | 2017 | 1731 | 0.030 |
Why?
|
Program Development | 2 | 2011 | 1316 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2016 | 12244 | 0.020 |
Why?
|
Patient Credit and Collection | 1 | 2010 | 16 | 0.020 |
Why?
|
HIV | 2 | 2012 | 1604 | 0.020 |
Why?
|
Program Evaluation | 2 | 2011 | 2488 | 0.020 |
Why?
|
Laboratories | 1 | 2014 | 463 | 0.020 |
Why?
|
Poverty Areas | 1 | 2011 | 275 | 0.020 |
Why?
|
Community-Based Participatory Research | 1 | 2011 | 214 | 0.020 |
Why?
|
Drug Resistance, Microbial | 2 | 2005 | 862 | 0.020 |
Why?
|
Selection, Genetic | 1 | 2014 | 914 | 0.020 |
Why?
|
Internet | 1 | 2002 | 3064 | 0.020 |
Why?
|
Organizational Objectives | 1 | 2011 | 438 | 0.020 |
Why?
|
Financing, Personal | 1 | 2011 | 308 | 0.020 |
Why?
|
Geographic Information Systems | 1 | 2010 | 281 | 0.020 |
Why?
|
Registries | 1 | 2004 | 8091 | 0.020 |
Why?
|
Health Care Costs | 2 | 2011 | 3209 | 0.020 |
Why?
|
HIV Seronegativity | 1 | 2008 | 211 | 0.020 |
Why?
|
Psychology | 1 | 2009 | 356 | 0.020 |
Why?
|
Organizational Case Studies | 1 | 2007 | 299 | 0.020 |
Why?
|
Peer Group | 1 | 2011 | 635 | 0.020 |
Why?
|
Secondary Prevention | 1 | 2012 | 1530 | 0.020 |
Why?
|
Vulnerable Populations | 1 | 2011 | 686 | 0.020 |
Why?
|
Age Factors | 2 | 2013 | 18373 | 0.020 |
Why?
|
Cost Savings | 1 | 2011 | 925 | 0.020 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2009 | 657 | 0.020 |
Why?
|
Needs Assessment | 1 | 2011 | 1146 | 0.020 |
Why?
|
Infant, Newborn | 2 | 2019 | 25628 | 0.020 |
Why?
|
Education | 1 | 2008 | 543 | 0.020 |
Why?
|
Ambulatory Care | 2 | 2008 | 2708 | 0.020 |
Why?
|
Streptomycin | 1 | 2004 | 69 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2011 | 2539 | 0.020 |
Why?
|
Retreatment | 1 | 2006 | 610 | 0.010 |
Why?
|
Ethambutol | 1 | 2004 | 60 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2013 | 6366 | 0.010 |
Why?
|
Risk | 1 | 2016 | 9688 | 0.010 |
Why?
|
Cooperative Behavior | 1 | 2011 | 1504 | 0.010 |
Why?
|
World Health Organization | 2 | 2000 | 1318 | 0.010 |
Why?
|
Infection Control | 1 | 2010 | 965 | 0.010 |
Why?
|
Survival Rate | 2 | 2012 | 12788 | 0.010 |
Why?
|
Disease Progression | 1 | 2019 | 13285 | 0.010 |
Why?
|
Public Health Administration | 1 | 2005 | 240 | 0.010 |
Why?
|
Inservice Training | 1 | 2004 | 392 | 0.010 |
Why?
|
Community Health Centers | 1 | 2005 | 430 | 0.010 |
Why?
|
Regression Analysis | 1 | 2011 | 6459 | 0.010 |
Why?
|
Health Plan Implementation | 1 | 2004 | 352 | 0.010 |
Why?
|
Feeding Behavior | 1 | 2014 | 3188 | 0.010 |
Why?
|
Antibodies, Viral | 1 | 2012 | 3177 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2004 | 10943 | 0.010 |
Why?
|
Mutation | 1 | 2005 | 29786 | 0.010 |
Why?
|
Practice Guidelines as Topic | 2 | 2011 | 7281 | 0.010 |
Why?
|
Patient Care Team | 1 | 2011 | 2531 | 0.010 |
Why?
|
Odds Ratio | 1 | 2012 | 9849 | 0.010 |
Why?
|
Communicable Disease Control | 1 | 2006 | 857 | 0.010 |
Why?
|
Pilot Projects | 1 | 2012 | 8319 | 0.010 |
Why?
|
Databases, Factual | 1 | 2014 | 7730 | 0.010 |
Why?
|
Quality Improvement | 1 | 2014 | 3749 | 0.010 |
Why?
|
Logistic Models | 1 | 2013 | 13409 | 0.010 |
Why?
|
Recurrence | 1 | 2010 | 8340 | 0.010 |
Why?
|
Sampling Studies | 1 | 2000 | 623 | 0.010 |
Why?
|
Genotype | 1 | 2013 | 12952 | 0.010 |
Why?
|
Severity of Illness Index | 2 | 2008 | 15535 | 0.010 |
Why?
|
Probability | 1 | 2004 | 2506 | 0.010 |
Why?
|
Electromyography | 1 | 2003 | 1379 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2004 | 2887 | 0.010 |
Why?
|
Health Planning | 1 | 1998 | 238 | 0.010 |
Why?
|
Age Distribution | 1 | 2003 | 2902 | 0.010 |
Why?
|
Risk Assessment | 3 | 2004 | 23336 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2012 | 15078 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2008 | 8642 | 0.010 |
Why?
|
International Cooperation | 1 | 2003 | 1420 | 0.010 |
Why?
|
Healthcare Disparities | 1 | 2011 | 3154 | 0.010 |
Why?
|
Morals | 1 | 1998 | 285 | 0.010 |
Why?
|
Pregnancy | 2 | 2009 | 29144 | 0.010 |
Why?
|
Boston | 1 | 2007 | 9312 | 0.010 |
Why?
|
Body Mass Index | 1 | 2012 | 12720 | 0.010 |
Why?
|
Nurses | 1 | 2004 | 2462 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2005 | 4805 | 0.010 |
Why?
|
HIV-1 | 1 | 2009 | 6939 | 0.010 |
Why?
|
Health Personnel | 1 | 2004 | 3219 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2003 | 3610 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2015 | 57776 | 0.010 |
Why?
|
Health Surveys | 1 | 2000 | 4036 | 0.010 |
Why?
|
Disease Management | 1 | 1999 | 2460 | 0.010 |
Why?
|
Mental Disorders | 1 | 2008 | 6600 | 0.000 |
Why?
|
Cost-Benefit Analysis | 1 | 1999 | 5390 | 0.000 |
Why?
|
Animals | 1 | 2009 | 168770 | 0.000 |
Why?
|